Wednesday, July 8, 2026

pharma · Nasopharyngeal Carcinoma · Hepatocellular Carcinoma

Chinese Academy of

Chinese Academy of is a pharma organization headquartered in TAIZHOU, CN. Primary therapeutic focus areas include Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, COVID-19, Breast Cancer, Coronary Artery Disease. Nova

China, TAIZHOU, CN HQ
170 Employees
NMPA registrant Type
Company details
Status
Public
HQ
China, TAIZHOU, CN
Employees
170
Programs
1328
Drugs
711
Patents
335
Clinical program

LVIVO-TaVec400 product

Phase 1 · mab · Multiple Myeloma (MM)

LVIVO-TaVec400 product for Multiple Myeloma (MM) is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Internal code IIT2025143

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase
Phase 1
Modality
mab
Indication
Multiple Myeloma (MM)
Status
active
Trials
1

Clinical trials